“Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s196, https://doi.org/10.25251/skin.7.supp.196.